Aquestive Therapeutics (NASDAQ:AQST) Insider Lori Braender Sells 40,102 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Lori Braender sold 40,102 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $167,225.34. Following the transaction, the insider owned 442,879 shares of the company’s stock, valued at $1,846,805.43. This trade represents a 8.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Aquestive Therapeutics Price Performance

Shares of AQST stock traded up $0.11 during trading hours on Wednesday, reaching $4.31. The company had a trading volume of 1,170,828 shares, compared to its average volume of 5,614,740. The company has a market cap of $525.38 million, a price-to-earnings ratio of -5.52 and a beta of 1.61. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $7.55. The business has a fifty day simple moving average of $4.13 and a 200-day simple moving average of $5.22.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to analyst estimates of $13.28 million. On average, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Trending Headlines about Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AQST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $8.80.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently made changes to their positions in AQST. NewEdge Advisors LLC purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter worth about $28,000. BNP Paribas Financial Markets increased its holdings in Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares during the last quarter. Modern Wealth Management LLC purchased a new stake in Aquestive Therapeutics during the second quarter worth about $33,000. Cox Capital Mgt LLC bought a new stake in Aquestive Therapeutics in the third quarter worth about $59,000. Finally, Kestra Private Wealth Services LLC purchased a new position in Aquestive Therapeutics in the third quarter valued at about $60,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.